[go: up one dir, main page]

SV2010003770A - Composicion y proceso- 356 - Google Patents

Composicion y proceso- 356

Info

Publication number
SV2010003770A
SV2010003770A SV2010003770A SV2010003770A SV2010003770A SV 2010003770 A SV2010003770 A SV 2010003770A SV 2010003770 A SV2010003770 A SV 2010003770A SV 2010003770 A SV2010003770 A SV 2010003770A SV 2010003770 A SV2010003770 A SV 2010003770A
Authority
SV
El Salvador
Prior art keywords
composition
formula
preparation
sulfate
see formula
Prior art date
Application number
SV2010003770A
Other languages
English (en)
Inventor
Helen Blade
Gwydion Huw Churchill
Angela Charlotte Currie
Benjamin Charles Dobson
Peter Samuel Hynes
Martin Neal Kenworthy
Lyn Powell
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2010003770A publication Critical patent/SV2010003770A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE ESTIPULA UN PROCESO PARA LA PREPARACIÓN DE UN COMPUESTO DE FÓRMULA 1: (VER FORMULA); EL USO DE DICHO PROCESO EN LA PREPARACIÓN DE UN COMPUESTO DE FÓRMULA 5: (VER FORMULA); O DE UNA DE SUS SALES DE FOSFATO, SULFATO, SULFATO ÁCIDO, MALATO, CITRATO, TARTRATO O FUMARATO, Y EL USO DE LA SAL DE FUMARATO EN UNA COMPOSICIÓN PARA USAR EN TERAPIA
SV2010003770A 2008-06-20 2010-12-20 Composicion y proceso- 356 SV2010003770A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7418808P 2008-06-20 2008-06-20
US15235009P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
SV2010003770A true SV2010003770A (es) 2011-05-20

Family

ID=41051136

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2010003770A SV2010003770A (es) 2008-06-20 2010-12-20 Composicion y proceso- 356

Country Status (26)

Country Link
US (1) US8198441B2 (es)
EP (1) EP2303875B1 (es)
JP (1) JP5607614B2 (es)
KR (1) KR101668497B1 (es)
CN (1) CN102137860B (es)
AR (1) AR072263A1 (es)
AU (1) AU2009261688B2 (es)
BR (1) BRPI0914912A2 (es)
CA (1) CA2728183C (es)
CL (1) CL2010001488A1 (es)
CO (1) CO6351729A2 (es)
CR (1) CR11859A (es)
DO (1) DOP2010000391A (es)
EA (1) EA019092B1 (es)
EC (1) ECSP10010696A (es)
ES (1) ES2398423T3 (es)
IL (1) IL210074A (es)
MX (1) MX2010014230A (es)
MY (1) MY172107A (es)
NI (1) NI201000225A (es)
PE (1) PE20110147A1 (es)
SV (1) SV2010003770A (es)
TW (1) TWI441821B (es)
UY (1) UY31917A (es)
WO (1) WO2009153597A2 (es)
ZA (1) ZA201101861B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0908100A2 (pt) * 2008-02-21 2015-10-06 Astrazeneca Ab produto combinação, uso de um composto, e, método de tratar câncer
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
EP4302827A3 (en) 2018-06-15 2024-03-13 JANSSEN Pharmaceutica NV Rapamycin analogs and uses thereof
MX2022006807A (es) 2019-12-05 2022-09-12 Anakuria Therapeutics Inc Análogos de rapamicina y usos de estos.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560685A (en) 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
PT1481970E (pt) 1999-09-07 2006-07-31 Syngenta Participations Ag Novos herbicidas
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ES2518316T3 (es) 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
CA2612788A1 (en) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
US20070128658A1 (en) * 2005-11-14 2007-06-07 Blackwell Helen E Fluorescent dyes, methods and uses thereof
WO2007060404A1 (en) * 2005-11-22 2007-05-31 Kudos Pharmaceuticals Limited PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
MY148688A (en) * 2006-08-23 2013-05-31 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2010004074A (es) * 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.

Also Published As

Publication number Publication date
ECSP10010696A (es) 2011-01-31
KR20110027789A (ko) 2011-03-16
CN102137860A (zh) 2011-07-27
TWI441821B (zh) 2014-06-21
MX2010014230A (es) 2011-03-29
AR072263A1 (es) 2010-08-18
EP2303875A2 (en) 2011-04-06
ES2398423T3 (es) 2013-03-19
WO2009153597A2 (en) 2009-12-23
HK1155160A1 (en) 2012-05-11
EP2303875B1 (en) 2012-11-28
IL210074A (en) 2015-07-30
CR11859A (es) 2011-02-25
KR101668497B1 (ko) 2016-10-21
BRPI0914912A2 (pt) 2017-06-20
CN102137860B (zh) 2013-08-28
AU2009261688B2 (en) 2012-07-05
US20090318434A1 (en) 2009-12-24
CA2728183A1 (en) 2009-12-23
TW201012818A (en) 2010-04-01
AU2009261688A1 (en) 2009-12-23
CA2728183C (en) 2016-10-25
CL2010001488A1 (es) 2011-07-15
CO6351729A2 (es) 2011-12-20
JP5607614B2 (ja) 2014-10-15
ZA201101861B (en) 2011-11-30
US8198441B2 (en) 2012-06-12
WO2009153597A3 (en) 2010-05-06
PE20110147A1 (es) 2011-03-26
EA201100063A1 (ru) 2011-10-31
UY31917A (es) 2010-01-29
NI201000225A (es) 2011-12-15
DOP2010000391A (es) 2011-01-15
MY172107A (en) 2019-11-14
EA019092B1 (ru) 2014-01-30
IL210074A0 (en) 2011-02-28
JP2011524889A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
SV2010003770A (es) Composicion y proceso- 356
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
EA201100030A1 (ru) Пиразольные соединения 436
CO6630136A2 (es) Procedimiento para la preparación de 4-{4[({4-cloro-3-(trifluorometil) fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carbocamida, sus sales y su monohidrato
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
BR112012003592B8 (pt) composição farmacêutica contendo derivado de quinolina
JO2885B1 (en) Protein kinase inhibitors
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
HRP20110807T1 (hr) Supstituirani pirimidodiazepini korisni kao plk1 inhibitori
MX339252B (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
EA201370191A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
MX2010009401A (es) Forma cristalina de derivado de fenilamino pirimidina.
EA200900707A1 (ru) Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
CY1109743T1 (el) Παραγωγα των 2-βενζοϋλο-ιμιδαζοπυριδινων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη
EA200900732A1 (ru) Кристаллическая калиевая соль аналогов липоксина а
EA200800777A1 (ru) Применение сложных эфиров молочной кислоты для улучшения действия пестицидов
CR10989A (es) Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
EA201071425A1 (ru) Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
CU20100253A7 (es) Composiciones y proceso-365
EP2582712A4 (en) NETWORKED PURINTERIN-HPPK INHIBITORS AS ANTIBACTERIAL ACTIVE SUBSTANCES
HRP20110468T1 (hr) 3-(2,2,2-trimetilhidrazinij) sol na bazi propionata za uporabu u liječenju miokardijalne infarkcije

Legal Events

Date Code Title Description
FD Lapse